Scala Biodesign Company Profile

Background

Overview

Founded in 2022 and headquartered in Tel Aviv, Israel, Scala Biodesign is a biotechnology company specializing in computational protein design. The company leverages artificial intelligence (AI), physics-based modeling, and biological data analysis to engineer proteins with enhanced properties, aiming to revolutionize applications across pharmaceuticals, food technology, and industrial processes.

Mission and Vision

Scala Biodesign's mission is to empower industries by providing advanced computational solutions that accelerate the development of proteins into commercial products. Their vision is to harness the potential of proteins to create more effective therapeutics, affordable food products, and sustainable chemical manufacturing processes.

Key Strategic Focus

Core Objectives

Accelerated Protein Development: Streamline the transformation of natural proteins into industrial-grade products by optimizing properties such as potency, stability, and manufacturability.

Cross-Industry Applications: Apply protein engineering solutions to diverse sectors, including pharmaceuticals, food technology, and sustainable chemistry.

Specialization and Technologies

Computational Protein Design: Utilize AI-driven computational methods to design proteins with superior properties.

PROSS Algorithm: Developed at the Weizmann Institute of Science, this algorithm enables the redesign of natural proteins to improve attributes like half-life, thermal stability, and expression levels.

Target Markets

Pharmaceutical Industry: Enhancing drug development through improved antibodies and enzymes.

Food Technology: Developing proteins for innovative food products.

Industrial Processes: Creating enzymes for sustainable chemical manufacturing.

Financials and Funding

Funding History

Seed Round: In September 2023, Scala Biodesign secured $5.5 million in seed funding led by TLV Partners.

Investors

TLV Partners: An Israeli venture capital firm specializing in early-stage startups.

Intel Ignite: An accelerator/incubator program supporting innovative technology companies.

Utilization of Capital

The funds are allocated to accelerate and enhance the development of proteins for biotechnology applications, focusing on expanding computational capabilities and broadening industry collaborations.

Pipeline Development

Key Projects

Malaria Vaccine Enhancement: Utilized computational methods to improve a malaria vaccine currently in Phase II clinical trials in West Africa.

Biofuel Production Enzymes: Developed wood-degrading enzymes to facilitate biofuel production.

Timelines

Specific timelines for these projects are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

PROSS Algorithm: A proprietary algorithm for redesigning natural proteins to enhance stability and expression levels.

Scientific Methodologies

AI and Machine Learning: Employ AI-driven computational solutions to design proteins with superior properties.

Physics-Based Modeling: Integrate physics-based modeling to predict and optimize protein structures.

Leadership Team

Dr. Ravit Netzer, Co-Founder & Chief Executive Officer: Holds a Ph.D. from the Weizmann Institute of Science, with expertise in protein engineering.

Dr. Adi Goldenzweig, Co-Founder & Chief Technology Officer: Also a Ph.D. graduate from the Weizmann Institute, specializing in computational protein design.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been reported.

Competitor Profile

Market Insights and Dynamics

The protein engineering market is experiencing significant growth, driven by advancements in biotechnology and increasing demand for protein-based therapeutics and industrial enzymes.

Competitor Analysis

AlphaFold by DeepMind: Utilizes AI and machine learning to predict protein structures, facilitating drug discovery.

Other Competitors: While specific competitors are not detailed, the field includes various biotech firms focusing on protein engineering and computational biology.

Strategic Collaborations and Partnerships

Scala Biodesign is collaborating with several pharmaceutical companies on protein engineering projects, leveraging its computational platform to address complex challenges in drug development.